STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer

By sjmartinez • July 23, 2024

Saeed A, Tabernero J, Parikh A, den Eynde MV, Karthaus M, Gerlinger M, Wang Z, Wang G, Smith R, Hecht JR. STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer. Future Oncol. 2024 Jul 23:1-11. doi: 10.1080/14796694.2024.2352276. Epub ahead of print. PMID: 39041200.

Tags: Hematology/Oncology, Publications

Related Posts

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu[...]

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]